Previous studies showed that tumour DNA methylation profiles could significantly differentiate the immune cell proportions in the TME, including TILs [99], whereas the methylation of promoters CTLA4, LAG3, and PD-L1 was largely associated with longer survival and a longer duration of response when immunotherapy was used [100]. Here, CTLA4 is linked to neoplasm.